Phase 3 RCT of subcutaneous anifrolumab vs placebo in adults with moderate to severe SLE: at the interim analysis (220 patients) BICLA response at week 52 was 59.4% vs 43.9%; herpes zoster 3.8% vs 1.1% in the full analysis (367).
RCTn = 367
Manzi et al. Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study